US · VOR
Vor Biopharma Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02140
- Website
- vorbio.com
Price · as of 2024-12-31
$13.85
Market cap 105.82M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $888.00 | ||||
| 2021 | $170.20 | ||||
| 2022 | $93.60 | ||||
| 2023 | $46.80 | ||||
| 2024 | $20.00 |
AI valuation
Our deep-learning model estimates Vor Biopharma Inc.'s (VOR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $13.85
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VOR | Vor Biopharma Inc. | $13.85 | 105.82M | — | — | — | — | -0.59 | 0.71 | — | -0.07 | — | 0.71 | 0.00% | — | — | -94.52% | -282.56% | -66.29% | 0.33 | — | 5.19 | 4.94 | 0.43 | -286.00% | — | -145.00% | -145.39% | -5.35 | -232.90% | 0.00% | 0.00% | 79.21% | -0.07 | -0.09 | — | -5.73 |
| ACTU | Actuate Therapeutics Inc | $3.74 | 86.93M | — | — | — | — | -4.97 | 1301.78 | — | -5.05 | -5.09 | 1301.78 | 0.00% | — | — | 54.83% | 45.28% | -443.16% | 0.00 | 1344.27 | 1.05 | 0.98 | 0.34 | 9758.00% | — | 101.00% | -16.10% | -2.48 | 39.31% | 0.00% | 0.00% | 4.19% | -5.05 | -5.81 | — | -19.92 |
| ALEC | Alector, Inc. | $2.43 | 265.24M | +1,084% | -64% | — | +3,751% | -1.59 | 7.43 | 10.82 | -0.06 | -12.24 | 7.43 | 54.09% | -692.83% | -679.16% | -181.56% | 67.31% | -37.54% | 1.18 | — | 3.83 | 3.68 | 0.22 | 1301.00% | -7907.00% | -2037.00% | -80.87% | -2.65 | 84.98% | 0.00% | 0.00% | 17.16% | -0.05 | -0.04 | 0.37 | -4.88 |
| ANIX | Anixa Biosciences, Inc. | $2.98 | 99.47M | — | — | — | — | -9.95 | 7.24 | — | -8.10 | — | 7.24 | 0.00% | — | — | -62.73% | -4708.65% | -58.55% | 0.01 | — | 8.08 | 7.71 | 0.09 | -1282.00% | — | -221.00% | -6.54% | -3.65 | -2886.52% | 0.00% | 0.00% | 0.00% | -8.10 | -13.21 | — | 7.63 |
| APLT | Applied Therapeutics, Inc… | $0.10 | 14.86M | +30,191% | +123% | — | +60,988% | -0.76 | 1.40 | 175.54 | -0.03 | — | 1.40 | 100.00% | -22922.86% | -23214.07% | -529.97% | 242.94% | -149.27% | 0.05 | — | 3.06 | 2.91 | 0.74 | -4648.00% | -9545.00% | 5280.00% | -105.55% | -3.09 | 196.37% | 0.00% | 0.00% | 34.41% | -0.03 | -0.04 | 7.18 | -10.84 |
| FATE | Fate Therapeutics, Inc. | $1.48 | 170.72M | +1,664% | -45% | — | +3,067% | -1.31 | 0.86 | 26.81 | -0.41 | — | 0.86 | -94.12% | -2222.45% | -2051.08% | -51.84% | -143.19% | -35.89% | 0.38 | — | 5.79 | 5.67 | -0.25 | -2988.00% | -5124.00% | -936.00% | -62.88% | -2.94 | -108.62% | 0.00% | 0.00% | 10.10% | -0.35 | -0.47 | 7.88 | -6.64 |
| FBRX | Forte Biosciences, Inc. | $30.22 | 378.56M | — | — | — | — | -0.53 | 0.36 | — | 1.11 | — | 0.36 | 0.00% | — | — | -80.82% | 951.20% | -70.57% | 0.00 | — | 6.76 | 6.43 | 0.63 | -5116.00% | — | 690.00% | -162.41% | -3.39 | 799.95% | 0.00% | 0.00% | 54.26% | 1.08 | 1.28 | — | -3.19 |
| MCRB | Seres Therapeutics, Inc. | $8.74 | 79.07M | — | — | — | — | 875.27 | 8.64 | — | -1.50 | 14208.58 | 8.64 | 0.00% | — | — | -0.88% | -241.20% | 0.05% | 6.65 | — | 0.94 | 0.86 | -0.51 | 616.00% | — | 1888.00% | -125.16% | -3.61 | -296.22% | 0.00% | 0.00% | 8.38% | -1.48 | -1.21 | — | -12.11 |
| NKTX | Nkarta, Inc. | $2.70 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
| PEPG | PepGen Inc. | $6.22 | 427.61M | — | — | — | — | -0.81 | 0.61 | — | 0.32 | — | 0.61 | 0.00% | — | — | -79.26% | -551.43% | -61.23% | 0.16 | — | 7.41 | 7.20 | 0.35 | -1364.00% | — | 1575.00% | -113.83% | -4.93 | -470.74% | 0.00% | 0.00% | 0.00% | 0.29 | 0.35 | — | -2.45 |
| SPRO | Spero Therapeutics, Inc. | $2.17 | 122.26M | +1,351% | -86% | — | +2,434% | -0.61 | 0.91 | 0.88 | 0.09 | — | 0.91 | -101.67% | -152.91% | -142.91% | -89.62% | -436.22% | -46.81% | 0.09 | — | 2.19 | 2.15 | 0.67 | -39535.00% | -5377.00% | -2895.00% | -55.69% | -0.48 | -139.40% | 0.00% | 0.00% | 0.00% | 0.09 | 0.28 | -0.14 | -6.55 |
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- CEO
- Jean-Paul Kress
- Employees
- 159
- Beta
- 2.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $13.85) − 1 = — (DCF, example).